الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Chronic infection with HCV is considered as leading cause of liver cirrhosis and hepatocellular carcinoma in most of cases. A new era in HCV treatment has been started using direct acting antiviral activity (DAA). Among the approved DAA drugs were Sofosbuvir, Simeprevir and Daclatasvir. The patients classified into two groups.
group A: Contain 175 patients and received Simeprevir (150 mg) and Sofosbuvir (400 mg) (SMV/SOF) once daily for 12 weeks. group B: Contain 150 patients who were eligible to be treated by the following regimen for 12 weeks once daily Daclatasvir 60 mg and Sofosbuvir 400 mg (DCV/SOF) with ribavirin 1200 mg.
On the basis of the evidence currently available, it seems fair to suggest that the combination therapies (SMV/SOF) and (DCV/SOF with RBV) in the treatment of chronic HCV genotype IV naïve and experienced patient were safe and effective.